NCT06085755 2025-12-15
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Samsung Medical Center
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT01649271 2025-02-11
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT01522768 2023-11-01
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02501603 2023-01-27
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
Yonsei University
Phase 2 Completed